Virus News and Research

Latest Virus News and Research

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Raycop, the first handheld anti-bacterial vacuum cleaning system and part of the Earlex® brands, offers a proven way to fight the H1N1 virus in the home with its UVC technology. The vac's effects against the virus have been independently tested by a leading international laboratory in August.

3 Nov 2009

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Community pharmacists have stepped up to meet the shortage of Tamiflu by compounding doses for children suffering from the H1N1 flu virus, but they are struggling with supply problems and insurance plans, according to the National Community Pharmacists Association.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.

3 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

3 Nov 2009

FDA: Guidance document on diagnostic tests for the 2009 H1N1 influenza virus

The U.S. Food and Drug Administration today published a guidance document that should help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus. Although there are not any FDA-approved or cleared tests that diagnose this specific infection, during this pandemic, manufacturers can submit a request to the FDA for an Emergency Use Authorization (EUA).

3 Nov 2009

Swine flu vaccine supply expected to increase 'in short order'

A senior adviser to President Barack Obama says the government "overpromised" with the swine flu vaccine but that the vaccine supply would catch up with the demand within a week. Meanwhile, a health group established to monitor the vaccine's safety will begin work this week.

3 Nov 2009

Deaths from H1N1 rise by 700 in one week, WHO reports

The number of deaths from H1N1 (swine flu) rose by 700 in a week, to top 5,700 since the virus was first identified in April, the WHO reported Friday, Agence France-Presse reports (10/30).

2 Nov 2009

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.

2 Nov 2009

A look at the odds associated with the influenza virus

What are the odds you will be one of the unlucky ones who gets the flu this year? Book of Odds has launched "Flu Week," a fascinating look at the odds associated with the influenza virus.

2 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Historic agreement sets national standard for containing the spread of H1N1

In a dramatic settlement seen as a novel pattern for the nation, the nation's largest nurses union and professional association, and one of the country's biggest hospital systems today announced a landmark agreement that sets a national standard on containing the spread of pandemics such as H1N1 "swine flu."

2 Nov 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

Results from two significant Canadian studies underscore the growing scientific evidence of PEGETRON's positive outcomes in the treatment of chronic hepatitis C virus (HCV) infection. Canadian investigators across the country collaborated to generate and analyze clinical data from the Canadian PEGETRON POWeR (Prospective Optimal Weight-based Dosing Response) and REDIPEN programs, which were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston on November 1, 2009.

2 Nov 2009

Humana reports higher consolidated revenues for third quarter at $7.72 billion

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2009 (3Q09) of $1.78, consistent with management’s guidance of $1.75 to $1.80. The company earned $1.09 per share for the quarter ended September 30, 2008 (3Q08) which reflected $0.40 per share in realized losses primarily associated with other-than-temporary impairments in investments and sales of distressed financial institution securities.

2 Nov 2009

AHF/Cambodia CARES to launch its AIDS testing initiative during the annual Water Festival

As part of an ambitious global effort to test several million people for HIV in observance of the Testing Millions World AIDS Day 2009 campaign, AHF/Cambodia CARES will launch its inaugural testing effort during the annual Water Festival, which marks the end of the rainy season and is the largest festival in the Cambodian calendar.

2 Nov 2009

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.

2 Nov 2009

Virus News and Research

Latest Virus News and Research

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Interim data from Schering-Plough's narlaprevir Phase IIa study

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

Mechanical force switches T cell from disease-scanning to disease-fighting mode

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

FDA: Guidance document on diagnostic tests for the 2009 H1N1 influenza virus

Swine flu vaccine supply expected to increase 'in short order'

Deaths from H1N1 rise by 700 in one week, WHO reports

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

A look at the odds associated with the influenza virus

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Historic agreement sets national standard for containing the spread of H1N1

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix raises $30.2 million through Series B financing

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

Humana reports higher consolidated revenues for third quarter at $7.72 billion

AHF/Cambodia CARES to launch its AIDS testing initiative during the annual Water Festival

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in